Skip to content

Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of nandrolone decanoate therapy and therapy with complex physiotherapy and diet in the treatment of sarcopenia

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517178-48-00
Acronym
NIGRIR_002SARKOPENIA
Enrollment
168
Registered
2024-10-31
Start date
2023-03-15
Completion date
Unknown
Last updated
2024-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia is characterized by loss of the muscle mass and function. It develops with age and is associated with a high risk of functional loss in complex activities of daily living, deterioration and quality of life, falls and injuries, patient institutionalization, hospitalization, and mortality in older adults.

Brief summary

Change in physical fitness as assessed by the SPPB test score (4- meter gait speed test version) in points, at the 5th study visit relative to the test score performed at visit 1, Change in the 400-meter walk test score in time units, at the 5th test visit, relative to the test score taken at visit 1

Interventions

Sponsors

Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in physical fitness as assessed by the SPPB test score (4- meter gait speed test version) in points, at the 5th study visit relative to the test score performed at visit 1, Change in the 400-meter walk test score in time units, at the 5th test visit, relative to the test score taken at visit 1

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026